Non-GCB subtype of DLBCL with high Ki-67 index and overexpression of MYC and BCL2 proteins (double expression), insensitive to the standard first-line treatment show poor prognostic significance (31). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.